Glecaprevir and Pibrentasvir for HCV in Kidney Disease
A 12-week treatment of glecaprevir and pibrentasvir in stage 4 or 5 chronic kidney disease patients with hepatitis C (HCV) resulted in a high response rate.
v6.7. We're a human-curated search engine and would love your feedback.
Glecaprevir and Pibrentasvir for HCV in Kidney Disease is live in our index. Now claim the top position. Featured sites are pinned above all standard results on the homepage, in their category, and across their target keywords. Rank is determined by remaining duration: the more years you hold, the higher you appear. Choose 1 year or more to secure the #1 position in Nephrology, or choose 18 years to secure the #1 position across all of Viesearch.
This is how this site will appear in search results with the Premium Featured plan.
A 12-week treatment of glecaprevir and pibrentasvir in stage 4 or 5 chronic kidney disease patients with hepatitis C (HCV) resulted in a high response rate.